Latest news with #Astrazeneca
Yahoo
6 days ago
- Business
- Yahoo
Astrazeneca (AZN) Stock Declines While Market Improves: Some Information for Investors
The latest trading session saw Astrazeneca (AZN) ending at $71.93, denoting a -1.24% adjustment from its last day's close. The stock fell short of the S&P 500, which registered a gain of 0.41% for the day. Meanwhile, the Dow experienced a rise of 0.08%, and the technology-dominated Nasdaq saw an increase of 0.67%. Shares of the pharmaceutical witnessed a gain of 0.54% over the previous month, beating the performance of the Medical sector with its loss of 3.74% and underperforming the S&P 500's gain of 6.13%. Investors will be eagerly watching for the performance of Astrazeneca in its upcoming earnings disclosure. On that day, Astrazeneca is projected to report earnings of $1.11 per share, which would represent year-over-year growth of 12.12%. Our most recent consensus estimate is calling for quarterly revenue of $14.03 billion, up 8.42% from the year-ago period. For the full year, the Zacks Consensus Estimates project earnings of $4.49 per share and a revenue of $57.68 billion, demonstrating changes of +9.25% and +6.67%, respectively, from the preceding year. It is also important to note the recent changes to analyst estimates for Astrazeneca. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the company's business health and profitability. Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system. The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.35% lower. As of now, Astrazeneca holds a Zacks Rank of #3 (Hold). In terms of valuation, Astrazeneca is currently trading at a Forward P/E ratio of 16.2. This valuation marks a discount compared to its industry's average Forward P/E of 20.51. It is also worth noting that AZN currently has a PEG ratio of 1.34. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. AZN's industry had an average PEG ratio of 1.47 as of yesterday's close. The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 74, which puts it in the top 30% of all 250+ industries. The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Don't forget to use to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AstraZeneca PLC (AZN) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
Daily Mail
30-04-2025
- Business
- Daily Mail
Step up now or lose jobs to US, AstraZeneca boss Pascal Soriot warns Europe
Astrazeneca's boss has warned Europe is falling behind as it steps up investment in the United States. Pascal Soriot said innovation in pharmaceuticals 'has mostly been funded by the US' as he doubled down on plans to grow the business in America – which already accounts for 40 per cent of revenues. And urging Europe to step up its game, he said AstraZeneca will shift manufacturing across the Atlantic to avoid tariffs on pharma imports planned by Donald Trump. 'When you see the amount of investment that is going into the US, it really sends a very strong signal that Europe has to contribute to pharmaceutical innovation a lot more,' said Soriot. 'Otherwise, all these jobs, whether they are manufacturing jobs or R&D jobs, are going to move to the US over time.' Trump has repeatedly said he will slap tariffs on drugs imports, which could make life-saving treatments more expensive for Americans and encourage firms such as AstraZeneca to produce more in the US. Warning against such tariffs, Soriot told Bloomberg TV: 'We actually believe that a better incentive to attract investment in manufacturing and in R&D is to have a great tax policy that incentivises companies to invest in the country.' But he added that AstraZeneca's exposure to tariffs would fall over time as it shifted production. 'Beyond 2025, any impact will be short-lived, because of the ability we have to move things around,' he said. 'Our company is firmly committed to investing and growing in the US. 'We have even greater US investment in manufacturing and R&D planned.' AstraZeneca – Britain's largest company with a value of £160billion – reported a 10 per cent increase in revenue for the first three months of 2025. The rise came after it made strong sales of cancer drugs, with the oncology division reporting a 13 per cent surge in business. Separately, AstraZeneca is awaiting a potential fine in China over possible unpaid import taxes. AstraZeneca said authorities in Shenzhen have claimed the unpaid taxes amount to £1.2million and that it could face a fine 'of between one and five times the amount of unpaid importation taxes' if found liable – or up to £6million. Despite the turmoil, Soriot said: 'We remain very committed to China. It's an important market for us.'
Bloomberg
30-04-2025
- Business
- Bloomberg
Trump Slams Powell Again, Tariff Toll Grows, Swiss Defense Stifled
Your morning briefing, the business news you need in just 15 minutes. On today's podcast: (1) President Donald Trump renewed criticism of Federal Reserve Chairman Jerome Powell as he championed his economic policies and tariff regime during a Tuesday event to mark his 100th day in office. (2) Trump also said China deserved the steep tariffs he imposed on their exports and predicted Beijing could find a way to reduce their impact on American consumers. (3) The European Union has made tangible offers to Donald Trump's administration in an effort to return stability to the global economy, according to the bloc's commissioner for international partnerships. (4) Companies around the world including carmakers, brewers, airlines and packaged food makers are sounding a warning that US President Donald Trump's import tariffs are beginning to wreak havoc on their businesses (5) Switzerland risks missing out on lucrative contracts due to its policy of neutrality as European nations rearm in the face of Moscow's aggression and tensions with the US. (6) Drugmaker Astrazeneca has told us it is seeing no particular benefit from the UK government's focus on economic growth. The company abandoned a planned £450 million investment in the UK at the start of this year.
Daily Mail
29-04-2025
- Business
- Daily Mail
Step up now or lose jobs to US, AstraZeneca boss Pascal Soriot warns European pharma firms
Astrazeneca's boss has warned Europe is falling behind as it steps up investment in the United States. Pascal Soriot said innovation in pharmaceuticals 'has mostly been funded by the US' as he doubled down on plans to grow the business in America – which already accounts for 40 per cent of revenues. And urging Europe to step up its game, he said AstraZeneca will shift manufacturing across the Atlantic to avoid tariffs on pharma imports planned by Donald Trump. 'When you see the amount of investment that is going into the US, it really sends a very strong signal that Europe has to contribute to pharmaceutical innovation a lot more,' said Soriot. 'Otherwise, all these jobs, whether they are manufacturing jobs or R&D jobs, are going to move to the US over time.' Trump has repeatedly said he will slap tariffs on drugs imports, which could make life-saving treatments more expensive for Americans and encourage firms such as AstraZeneca to produce more in the US. Warning against such tariffs, Soriot told Bloomberg TV: 'We actually believe that a better incentive to attract investment in manufacturing and in R&D is to have a great tax policy that incentivises companies to invest in the country.' But he added that AstraZeneca's exposure to tariffs would fall over time as it shifted production. 'Beyond 2025, any impact will be short-lived, because of the ability we have to move things around,' he said. 'Our company is firmly committed to investing and growing in the US. 'We have even greater US investment in manufacturing and R&D planned.' AstraZeneca – Britain's largest company with a value of £160billion – reported a 10 per cent increase in revenue for the first three months of 2025. The rise came after it made strong sales of cancer drugs, with the oncology division reporting a 13 per cent surge in business. Separately, AstraZeneca is awaiting a potential fine in China over possible unpaid import taxes. AstraZeneca said authorities in Shenzhen have claimed the unpaid taxes amount to £1.2million and that it could face a fine 'of between one and five times the amount of unpaid importation taxes' if found liable – or up to £6million. Despite the turmoil, Soriot said: 'We remain very committed to China. It's an important market for us.'
Yahoo
06-02-2025
- Business
- Yahoo
Seeking Clues to Astrazeneca (AZN) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics
In its upcoming report, Astrazeneca (AZN) is predicted by Wall Street analysts to post quarterly earnings of $1.07 per share, reflecting an increase of 46.6% compared to the same period last year. Revenues are forecasted to be $14.28 billion, representing a year-over-year increase of 18.8%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe. Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock. While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights. Bearing this in mind, let's now explore the average estimates of specific Astrazeneca metrics that are commonly monitored and projected by Wall Street analysts. According to the collective judgment of analysts, 'Alliance Revenue- Total' should come in at $615.99 million. The estimate suggests a change of +45.3% year over year. Analysts predict that the 'BioPharmaceuticals- CVRM- Crestor- World' will reach $250.88 million. The estimate indicates a change of +1.6% from the prior-year quarter. Analysts expect 'BioPharmaceuticals- CVRM- Seloken/Toprol-XL- World' to come in at $146.96 million. The estimate suggests a change of +2.1% year over year. The collective assessment of analysts points to an estimated 'Oncology- Zoladex- World' of $260.68 million. The estimate indicates a year-over-year change of +2.6%. The consensus estimate for 'BioPharmaceuticals- CVRM- Crestor- U.S.' stands at $12.07 million. The estimate points to a change of -19.6% from the year-ago quarter. The combined assessment of analysts suggests that 'Other Medicines- Nexium- U.S.' will likely reach $22.59 million. The estimate points to a change of -13.1% from the year-ago quarter. It is projected by analysts that the 'BioPharmaceuticals- R&I- Fasenra- U.S.' will reach $272.75 million. The estimate indicates a change of -0.8% from the prior-year quarter. Based on the collective assessment of analysts, 'BioPharmaceuticals- CVRM- Brilinta- U.S.' should arrive at $166.89 million. The estimate points to a change of -14% from the year-ago quarter. Analysts forecast 'Oncology- Lynparza- U.S.' to reach $357.31 million. The estimate points to a change of +1.5% from the year-ago quarter. The average prediction of analysts places 'Oncology- Imfinzi- U.S.' at $683.59 million. The estimate points to a change of +12.3% from the year-ago quarter. The consensus among analysts is that 'Oncology- Calquence- U.S.' will reach $574.82 million. The estimate points to a change of +20.3% from the year-ago quarter. Analysts' assessment points toward 'BioPharmaceuticals- CVRM- Farxiga- U.S.' reaching $435.80 million. The estimate points to a change of -3.4% from the year-ago all Key Company Metrics for Astrazeneca here>>>Shares of Astrazeneca have demonstrated returns of +6.8% over the past month compared to the Zacks S&P 500 composite's +2.7% change. With a Zacks Rank #3 (Hold), AZN is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AstraZeneca PLC (AZN) : Free Stock Analysis Report To read this article on click here. Zacks Investment Research Sign in to access your portfolio
